216 results on '"Walpole, E."'
Search Results
2. Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
3. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial
4. Lessons learned from a pilot study of an Indigenous patient navigator intervention in Queensland, Australia
5. Validation of a frailty index in older cancer patients with solid tumours
6. EP04.01-013 Frailty Index Predicts Treatment Outcomes in Older Adults with Lung Cancer
7. Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors
8. Additional file 1 of Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
9. Additional file 3 of Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
10. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
11. Health professionalʼs perspectives of the barriers and enablers to cancer care for Indigenous Australians
12. HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel
13. A SYSTEMATIC REVIEW OF VITAMIN D AND CANCER - PERILS OF DEFICIENCY AND IMPLICATIONS FOR PRACTICE: 601.
14. IgE Sequences in Individuals Living in an Area of Endemic Parasitism Show Little Mutational Evidence of Antigen Selection
15. Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility
16. Lung cancer patients in Queensland suffer delays in receiving radiation therapy – but not as a result of distance
17. Histopathology reporting of breast cancer in Queensland: the impact on the quality of reporting as a result of the introduction of recommendations
18. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus
19. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy
20. Improving patient outcomes in oncology: smart tools …: O124
21. Retrospective analysis of a single institutional experience with concurrent chemo-radiation for locally advanced nasopharyngeal carcinoma: O87
22. Unusual liver abscess
23. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia
24. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy
25. A COMPARISON OF TREATMENT OUTCOME BETWEEN ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA OF THE OESOPHAGUS
26. ASSESSING THE RESPONSE OF OESOPHAGEAL CARCINOMA TO NEOADJUVANT THERAPY USING OESOPHAGOGASTROSCOPY
27. Survival After Phase II Treatment of Advanced Renal Cell Carcinoma with Taxol or High-Dose Interleukin-2
28. Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors
29. Lessons learned from a pilot study of an Indigenous patient navigator intervention in Queensland, Australia
30. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies
31. An AGITG trial –A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel +/-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma
32. O-019 SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment
33. 1142 - Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies
34. 610O - An AGITG trial –A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel +/-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma
35. ORIGINAL ARTICLE: Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility
36. The shortage of medical oncologists and low chemotherapy utilization in Australia.
37. Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983).
38. Completeness of Histopathology Reporting of Melanoma in a High-Incidence Geographical Region
39. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma
40. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer
41. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases
42. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer
43. Outcomes and health status of patients undergoing usual care for highly emetogenic chemotherapy
44. Adjuvant chemotherapy for osteogenic sarcoma: Long-term follow-up from a single institution
45. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983
46. A single institution, retrospective chart review of relapse patterns in stage 1 non-seminomatous germ cell tumours (NSGCT)
47. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer
48. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy
49. Relapse Patterns after Chemo-radiation for Carcinoma of the Oesophagus
50. Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.